Su1082 – Link Between Portal Venous Free Fatty Acids and Hepatic Lipid Metabolism in Chronic Hepatitis C Before and After Hcv Clearance

Background/Aims: Olanzapine, an atypical antipsychotic drug, has therapeutic effects for schizophrenia. However, clinical reports indicate that patients taking atypical antipsychotic drugs are at high risk of metabolic syndrome with unclear mechanisms. We investigated the effect of olanzapine on atherosclerosis and the mechanisms in apolipoprotein E-null (apoE-/-) mice. Methods: ApoE-/- mice were used as in vivo models. Western blot analysis was used to evaluate protein expression. Conventional assay kits were applied to assess the levels of cholesterol, triglycerides, free cholesterol, cholesteryl ester, fatty acids, glycerol, and cytokines. Results: Daily treatment with olanzapine (3 mg/kg body weight) for four weeks increased mean arterial blood pressure and the whitening of brown adipose tissue in mice. In addition, olanzapine impaired aortic cholesterol homeostasis and exacerbated hyperlipidemia and aortic inflammation, which accelerated atherosclerosis in mice. Moreover, lipid accumulation in liver, particularly total cholesterol, free cholesterol, fatty acids, and glycerol, was increased with olanzapine treatment in apoE-/- mice by upregulating the expression of de novo lipid synthesis-related proteins and downregulating that of cholesterol clearance- or very low-density lipoprotein secretion-related proteins. Conclusion: Olanzapine may exacerbate atherosclerosis by deregulating hepatic lipid metabolism and worsening hyperlipidemia and aortic inflammation.

Download Full-text

ASSESSMENT OF CARDIAC FUNCTIONS IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS BEFORE AND AFTER TREATMENT WITH DIRECTLY ACTING ANTIVIRALS

Journal of the Egyptian Society of Parasitology ◽

10.21608/jesp.2021.193327 ◽

2021 ◽

Vol 51 (2) ◽

pp. 405-410

Author(s):

MOHAMED G. TALKAHN ◽

KHALED H. ABDEL MAGED ◽

HESHAM H. R. EL KILANY ◽

ESLAM S. MOHAMED ◽

HAITHAM G. MOHAMED ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Cardiac Functions ◽

Before And After ◽

Chronic Hepatitis C Patients

Download Full-text

Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection

World Journal of Gastroenterology ◽

10.3748/wjg.v19.i41.7055 ◽

2013 ◽

Vol 19 (41) ◽

pp. 7055 ◽

Cited By ~ 4

Author(s):

Mohammed Eslam

Keyword(s):

Insulin Resistance ◽

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Lipid Metabolism ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Hepatitis C Virus Infection ◽

Chronic Hepatitis C Virus

Download Full-text

Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE−/− Mice

Oxidative Medicine and Cellular Longevity ◽

10.1155/2018/6256802 ◽

2018 ◽

Vol 2018 ◽

pp. 1-12 ◽

Cited By ~ 5

Author(s):

Liang Liu ◽

Qinling Hu ◽

Huihui Wu ◽

Xiujing Wang ◽

Chao Gao ◽

...

Keyword(s):

Fatty Acids ◽

Fatty Acid ◽

Lipid Metabolism ◽

Liver Disease ◽

Inflammatory Responses ◽

Elevated Serum ◽

Serum Levels ◽

Hepatic Lipid Metabolism ◽

Hepatic Lipid ◽

Fa Composition

Diets containing various docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) ratios protect against liver damage in mice fed with a high-fat diet (HFD). However, it is unclear whether these beneficial roles of DHA and EPA are associated with alterations of fatty acid (FA) composition in the liver. This study evaluated the positive impacts of n-6/n-3 polyunsaturated fatty acids (PUFAs) containing different DHA/EPA ratios on HFD-induced liver disease and alterations of the hepatic FA composition. ApoE−/− mice were fed with HFDs with various ratios of DHA/EPA (2 : 1, 1 : 1, and 1 : 2) and an n-6/n-3 ratio of 4 : 1 for 12 weeks. After treatment, the serum and hepatic FA compositions, serum biochemical parameters, liver injury, and hepatic lipid metabolism-related gene expression were determined. Our results demonstrated that dietary DHA/EPA changed serum and hepatic FA composition by increasing contents of n-6 and n-3 PUFAs and decreasing amounts of monounsaturated fatty acids (MUFAs) and the n-6/n-3 ratio. Among the three DHA/EPA groups, the DHA/EPA 2 : 1 group tended to raise n-3 PUFAs concentration and lower the n-6/n-3 ratio in the liver, whereas DHA/EPA 1 : 2 tended to raise n-6 PUFAs concentration and improve the n-6/n-3 ratio. DHA/EPA supplementation reduced the hepatic impairment of lipid homeostasis, oxidative stress, and the inflammatory responses in HFD-fed mice. The DHA/EPA 2 : 1 group had lower serum levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol and higher levels of adiponectin than HFD group. The DHA/EPA 1 : 2 group had elevated serum levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase, without significant change the expression of genes for inflammation or hepatic lipid metabolism among the three DHA/EPA groups. The results suggest that DHA/EPA-enriched diet with an n-6/n-3 ratio of 4 : 1 may reverse HFD-induced nonalcoholic fatty liver disease to some extent by increasing n-6 and n-3 PUFAs and decreasing the amount of MUFAs and the n-6/n-3 ratio.

Download Full-text